OrbiMed-led $80M series B to help Adicet bring its γδ cell therapies to the clinic

Adicet raised $80 million in an untranched series B round led by existing investor OrbiMed to bring its first three off-the-shelf γδ T cell therapies to the clinic.

The company plans to submit in six months an IND

Read the full 372 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE